• Cyclerion Announces Sickle Cell Disease Study Results americanpharmaceuticalreview
    October 22, 2020
    Cyclerion Therapeutics announced top-line results from its STRONG-SCD study of olinciguat, an investigational, orally-administered, once daily, vascular sGC stimulator for the potential treatment of sickle cell disease (SCD).
PharmaSources Customer Service